Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1 μg/mL |
10 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
HeLa Cell Slide(GTX25529) , Human Placenta Tissue Lysate(GTX29186)
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
PLAC1 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human PLAC1.The immunogen is located within amino acids 130 - 180 of PLAC1.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
placenta enriched 1 , CT92 , OOSP2B , OOSP2L
Cellular Localization
Secreted
Background
PLAC1 was initially identified as a protein expressed specifically in the placenta and other cells derived from the trophoblast lineage during embryonic development, but has also been found to be expressed ectopically in a wide range of human malignancies, particularly breast cancers. PLAC1 is a membrane-associated protein that is thought to serve a receptor-like function modulating cell-cell or ligand receptor interactions unique to the maternal-placental interface. Decreased expression of PLAC1 is associated with decreased expression of cyclin D1 and reduced expression of AKT kinase, which, combined with the fact that PLAC1 is expressed on the surface of cancer cells, suggests that PLAC1 may be an effective candidate for immunotherapeutic treatments of cancer.
Database
Research Area